The effect of taurolidine on experimental thrombus formation

European Journal of Pharmacology

Volumn 578, Issue 2-3, 2008, Pages 238-241

  Kaptanoglu, Levent ^a   Kucuk, Hasan Fehmi ^a   Colak, Elif ^a   Kurt, Necmi ^a   Bingul, Sadik Mehmet ^a   Akyol, Huseyin ^a   Torlak, Oguzhan Aziz ^a   Yazici, Fatma ^a  

^a Kartal Research and Education Hospital   (Turkey)

Author keywords

Low molecular weight heparin; Taurolidine; Thrombus formation

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; SODIUM CHLORIDE; TAUROLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HYPERCOAGULABILITY; INFERIOR CAVA VEIN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; SERUM; THROMBOCYTE COUNT; THROMBOGENESIS; VEIN THROMBOSIS; VENOUS STASIS;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; LIGATION; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROTHROMBIN TIME; RATS; RATS, WISTAR; TAURINE; THIADIAZINES; VENA CAVA, INFERIOR; VENOUS THROMBOSIS;

EID: 37349045965     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.08.035     Document Type: Article

References (13)

1. Browne M.K. Pharmacological and clinical studies with taurolin. In: Brückner, and Pfirrmann (Eds). Taurolin. Ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infectionen (1985), Urban & Shwarzenberg, München 51-63
2. Browne M.K., MacKenzie M., and Doyle P.J. Control trial of taurolin in established bacterial peritonitis. Surg. Gynecol. Obstet. 146 (1978) 721-724
3. Fakhry S.M., Rutherford E.J., and Sheldon G.F. Hematologic principles in surgery. In: Towsend C.M. (Ed). Sabiston Textbook of Surgery. The Biological Basis of Modern Surgical Practise (2001), W.B. Saunders, Philadelphia 68-89
4. Green D., Hirsh J., Heit J., Prins M., Davidson B., and Lensing A.W. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol. Rev. 46 (1994) 89-109
5. Ji H., Li S.P., Cheng X., Cheng H.R., Ng T.B., Li P., and Li N.S. Antithrombotic effects of low-molecular-weight heparin calcium (LMWH-Ca) in experimental models. Gen. Pharmacol. 33 (1999) 207-211
6. Knight K.K., Wong J., Hauch O., Wygant G., Aguilar D., and Ofman J.J. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health 8 (2005) 191-200
7. Leaper D.J. Prevention of peritoneal adhesion after thermal injury using noxythiolin and taurolidin. In: Brückner, and Pfirrmann (Eds). Taurolin. Ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infectionen (1985), Urban & Shwarzenberg, München 115-119
8. Reeves D.S., and Schweitzer F.A.W. Experimental studies with an antibacterial substance-taurolin. Hell. Soc. Chemother. 2 (1974) 583-586
9. Reinmuller J. The influence of taurolidine on physiological and pathological blood coagulation and implications for its use. Zentralbl. Chir. 124 (1999) 13-18
10. Steinbach-Lebbin C., Ganz A.J., Chang A., and Waser P.G. Über diepharmakokinetik von taurolin. Pharmacokinetics of Taurolin. Arzneimittelforschung 32 (1982) 1542-1546
11. Waser P.G., Sibler E., and Ganz A.J. Pharmakologie und toxikologie von taurolidin. In: Brückner W.L., and Pfirrman R.W. (Eds). Taurolin. Ein neues konzept zur antimikrobiellen Chemotherapie chirurgisher infectionen (1985), Urban & Schwarzenberg, München 24-37
12. Weitz J. New anticoagulant strategies. Current status and future potential. Drugs 48 (1994) 485-497
13. Wessler S., Reimer S.M., and Sheps M.C. Biologic assay of a thrombosis inducing activity in human serum. J. Appl. Physiol. 14 (1959) 943-946